Canaccord Adams adds Orexigen Therapeutics (Nasdaq: OREX) to its Best Ideas list. The firm maintains its Buy rating and $21 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE